For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Tafamidis and Attruby represents a significant advancement . These innovative therapies stabilize the transthyretin protein, slowing its harmful build-up and alleviating the severi